Eric Small, MD
, a professor in residence of medicine and urology and interim chief of the Division of Hematology/Oncology, has been named director of investigational therapeutics in the UCSF Comprehensive Cancer Center.Frank McCormick, PhD
, director of the UCSF Comprehensive Cancer Center and Cancer Research Institute, recently announced the appointment.
Small is also a new leader of the cancer center's Prostate Cancer Program
, which ranks among the premier clinical and translational research programs in the country. It serves as the model at UCSF for a translational research program as it capitalizes on UCSF's strengths in imaging, informatics and laboratory-based target validation. Small has overseen an impressive portfolio of clinical trials in all phases of development.
Small also has experience both within and outside of UCSF that makes him particularly well suited to lead the investigational therapeutics initiative. He serves as institutional principal investigator for the Prostate Cancer Foundation Therapy Consortium as well as the newly designated Department of Defense Prostate Cancer Clinical Trials Consortium. Both of these consortia have focused on the implementation of early-phase, multi-center clinical trials with strong translational components.
Within the Division of Hematology/Oncology, Small also oversees a strong medical oncology group in genitourinary (GU) oncology with important therapeutic research focus in all GU malignancies, including bladder and kidney cancers.
(Note that in November 2007 the UCSF Comprehensive Cancer Center was renamed the UCSF Helen Diller Family Comprehensive Cancer Center.)
Read more at UCSF Today